TheraVet Broadens Its Bone Substitutes Portfolio With an Innovative Line of Biological Bone Grafts
07 Februar 2022 - 7:30AM
Business Wire
- Addition of a new line of biological bone grafts
complementary to existing line of synthetic bone grafts
- TheraVet bone substitutes’ offer now one of the most
comprehensive on the veterinary market
Regulatory News:
TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 -
ticker: ALVET), a pioneering company in the management of
osteoarticular diseases in pets, announces today an exclusive
partnership expanding TheraVet’s bone substitutes portfolio with a
new and complementary biological bone graft product line,
“BIOCERA-VET® SmartGraft.”
BIOCERA-VET® SmartGraft is a unique technology combining mineral
chips and bone-derived matrix developed for human orthopedic and
dental applications adapted and transposed to veterinary medicine.
BIOCERA-VET® SmartGraft will be available for the veterinary market
in different presentations – different granulometries (fine &
ultrafine) and volumes (from 1cc to 5cc) - in order to fulfil
veterinarian needs.
With this additional product line, TheraVet intends to
forcefully penetrate the market of bone allografts accounting for
23%1 of the bone substitutes market in the USA (at least as big as
the synthetic market) and 13%2 in Europe and United Kingdom.
BIOCERA-VET® SmartGraft is indeed well positioned against
competing products (i.e., allograft). It is osteoconductive,
biocompatible, biodegradable and supports fast and effective bone
regeneration thanks to its microstructure (porosity). Easier to
produce and manufactured to the highest human medical device
standards, BIOCERA-VET® SmartGraft offers better product
consistency and better product quality3. It is also non-species
specific, broadening its use across practices and facilitating the
life of veterinary surgeons. Finally, product shortage, regularly
encountered with bone allograft supply due to limited donor
sources, is prevented thanks to the unique composition.
With its new BIOCERA-VET® SmartGraft product line, TheraVet will
provide to the veterinary market a unique and standardized
biological bone graft solution combining quality with
availability.
Gianni Pertici Ph.D., Chief Executive Officer of Industrie
Biomediche Insubri SA, announces: “IBI believes that
regenerative medicine represents the future for health, actives
from more than 10 years in human regeneration technologies, we are
strongly convinced this is the right moment to invest and expand
our portfolio in the veterinary applications. After several months
of investigation, IBI recognizes in TheraVet SA the right and
strongest partner to achieve this important milestone.”
Enrico Bastianelli, Chief Executive Officer of TheraVet,
concludes: “After the recent additions of a wide range of
synthetic bone substitutes to BIOCERA-VET portfolio, this
partnership is another major step forward to position Theravet as
the undisputed leader in veterinary bone substitutes. We are
looking forward to our collaboration with IBI.”
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for animals. The Company develops
targeted, safe and effective treatments to improve the quality of
life of pets suffering from osteoarticular diseases. For pet
owners, the health of their pets is a major concern and TheraVet’s
mission is to address the need for innovative and curative
treatments. TheraVet works closely with international opinion
leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Gosselies, Belgium, and it has a subsidiary in the US.
For more information, visit the TheraVet Or follow us on
LinkedIn / Facebook / Twitter
_________________________________ 1 Based on market research
completed in 4Q2020 in United-States (Medistrat) 2 Based on market
research completed in 2Q2020 and 4Q2020 in Belgium, France,
Netherlands and Germany (Medistrat) 3 CE marked and classified as
class III Medical Device in human
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220206005020/en/
TheraVet Sabrina Ena Chief Operating Officer
Sabrina.ena@thera.vet Tel: +32 (0) 71 96 00 43 Julie Winand Chief
Corporate Officer julie.winand@thera.vet NewCap Investor
Relations and Financial Communications Théo Martin / Olivier
Bricaud theravet@newcap.eu Tel: +33 (0)1 44 71 94 94 Press
Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu Tel: +33
(0)1 44 71 00 15
TheraVet (EU:ALVET)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
TheraVet (EU:ALVET)
Historical Stock Chart
Von Apr 2023 bis Apr 2024